Drillon A, et al. Registrational results of LIBRETTO-001: a phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancer. Abstract PL02.08. WCLC 2019, 7-10 september, Barcelona, Spanje.
Zorginstituut adviseert over toelating pembrolizumab (Keytruda) bij TNBC
mei 2024 | Borstkanker